- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT07504120
Wpływ zdalnie prowadzonego pilatesu na fizyczne i psychologiczne wyniki u osób ze stwardnieniem rozsianym (MS)
Czy zdalnie prowadzone pilates wpływa na wyniki fizyczne i psychiczne u osób ze stwardnieniem rozsianym?
Objectives Objective 1: To determine the effects of a 16-week remotely delivered Pilates intervention on walking endurance, walking speed, balance, fatigue, and pain compared to a waitlist control group in individuals with MS.
Objective 2: To examine the impact of a 16-week remotely delivered Pilates intervention on depression & anxiety, cognitive function, and QOL compared to a waitlist control group in individuals with MS.
Aim Aim 1: To assess whether the 16-week remotely delivered Pilates intervention significantly improves walking endurance, walking speed, balance, fatigue, and pain compared to a waitlist control group in individuals with MS Aim 2: To investigate whether the 16-week remotely delivered Pilates intervention significantly improves depression & anxiety, cognitive function, and QOL compared to a waitlist control group in individuals with MS.
Hypothesis Hypothesis 1: The 16-week remotely delivered Pilates intervention will significantly improve walking endurance, walking speed, balance, fatigue, and pain compared to a waitlist control group in individuals with MS.
Hypothesis 2: Participants receiving the 16-week remotely delivered Pilates intervention will demonstrate significantly greater improvements in depression & anxiety, cognitive function, and QOL compared to a waitlist control group in individuals with MS.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
The current study will determine the feasibility and efficacy of a 16-week remotely delivered Pilates intervention for improving physical and psychological outcomes, and QOL, compared with a control condition, in individuals with MS. This represents a significant step forward in examining Pilates as an accessible, complementary therapy in MS.
Typ studiów
Zapisy (Szacowany)
Faza
- Nie dotyczy
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Illinois
-
Chicago, Illinois, Stany Zjednoczone, 60612
- Rekrutacyjny
- University of Illinois Chicago
-
Kontakt:
- Parisa Najafi, PhD
- Numer telefonu: 7735055923
- E-mail: pems@uic.edu
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Age 18 years or older
- Self-reported diagnosis of multiple sclerosis by a neurologist
- Relapse-free for the past 30 days before screening
- Able to speak and read English as the primary language
- Access to the internet and e-mail,
- Ability to use Zoom, and willingness to complete testing sessions and questionnaires
- Ambulatory without an assistive device (for example, cane)
- Low to moderate disability, defined as a score of 0-4 on the Patient-Determined Disease Steps (PDDS)
- Insufficiently active, defined as a score < 14 on the Godin Leisure-Time Exercise Questionnaire-Health Contribution Score (GLTEQ-HCS)
- Adequate visual ability and literacy to read materials printed in 14-point font
- Currently treated with a disease-modifying therapy
Exclusion Criteria:
- Pregnant
- Elevated risk for strenuous or maximal exercise, defined as more than one "Yes" response on the Physical Activity Readiness Questionnaire (PAR-Q) during screening
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Inny
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Pojedynczy
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Inny: Pilates group
Behavioral: Pilates group |
REMOTLY PILATES EXERCISE |
|
Brak interwencji: Control group
Waitlist Group |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Change from baseline in walking endurance (Six-Minute Walk Test distance)
Ramy czasowe: Baseline and 16 weeks (end of treatment)
|
Distance walked during the Six-Minute Walk Test (6MWT) will be measured in meters. The outcome is the change from baseline to 16 weeks in 6MWT distance. |
Baseline and 16 weeks (end of treatment)
|
|
Change from baseline in walking speed (Timed 25-Foot Walk)
Ramy czasowe: Baseline and 16 weeks (end of treatment)
|
Walking speed will be assessed using the Timed 25-Foot Walk (T25FW). The outcome is the change from baseline to 16 weeks in time to walk 25 feet, measured in seconds. |
Baseline and 16 weeks (end of treatment)
|
|
Change from baseline in balance (Berg Balance Scale)
Ramy czasowe: Baseline and 16 weeks (end of treatment)
|
Balance will be assessed using the Berg Balance Scale (BBS), a 14-item performance-based measure of static and dynamic balance. Each item is scored from 0 to 4, and the outcome will be the change from baseline to 16 weeks in the BBS total score (range 0-56), with higher scores indicating better balance and lower risk of falls. |
Baseline and 16 weeks (end of treatment)
|
|
Change from baseline in fatigue (Fatigue Severity Scale)
Ramy czasowe: Baseline and 16 weeks (end of treatment)
|
Fatigue will be measured using the Fatigue Severity Scale (FSS), a 9-item questionnaire assessing the impact of fatigue on daily functioning. Each item is rated from 1 to 7, and the outcome will be the change from baseline to 16 weeks in the FSS mean score (range 1-7), with higher scores indicating more severe fatigue. |
Baseline and 16 weeks (end of treatment)
|
|
Change from baseline in pain (Short-form McGill Pain Questionnaire)
Ramy czasowe: Baseline and 16 weeks (end of treatment)
|
Pain will be measured using the Short-form McGill Pain Questionnaire (SF-MPQ). The outcome is the change from baseline to 16 weeks in SF-MPQ total score. |
Baseline and 16 weeks (end of treatment)
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Change from baseline in cognitive processing speed (Symbol Digit Modalities Test)
Ramy czasowe: Baseline and 16 weeks (end of treatment)
|
Cognitive processing speed will be assessed using the Symbol Digit Modalities Test (SDMT). The outcome is the change from baseline to 16 weeks in SDMT total score, with higher scores indicating better processing speed. SDMT scores typically range from 0 to about 110 correct responses. |
Baseline and 16 weeks (end of treatment)
|
|
Change from baseline in verbal learning and memory (California Verbal Learning Test-II)
Ramy czasowe: Baseline and 16 weeks (end of treatment)
|
Verbal learning and memory will be assessed using the California Verbal Learning Test-II (CVLT-II). The outcome is the change from baseline to 16 weeks in CVLT-II total recall score, with higher scores indicating better verbal learning and memory. CVLT-II total recall scores typically range from 0 to about 80. |
Baseline and 16 weeks (end of treatment)
|
|
Change from baseline in visuospatial learning and memory (Brief Visuospatial Memory Test-Revised)
Ramy czasowe: Baseline and 16 weeks (end of treatment)
|
Visuospatial learning and memory will be assessed using the Brief Visuospatial Memory Test-Revised (BVMT-R). The outcome is the change from baseline to 16 weeks in BVMT-R total recall score, with higher scores indicating better visuospatial memory. BVMT-R total recall scores typically range from 0 to 36. |
Baseline and 16 weeks (end of treatment)
|
|
Change from baseline in depression symptoms
Ramy czasowe: Baseline and 16 weeks (end of treatment)
|
Depression will be measured using a validated questionnaire (e.g., the Hospital Anxiety and Depression Scale-Depression subscale or a similar instrument). The outcome is the change from baseline to 16 weeks in depression total score, with higher scores indicating greater depressive symptoms. Typical depression scales have ranges such as 0-21 (HADS-D) ; enter the exact range that matches the scale you are using. |
Baseline and 16 weeks (end of treatment)
|
|
Change from baseline in anxiety symptoms
Ramy czasowe: Baseline and 16 weeks (end of treatment)
|
Anxiety will be measured using a validated questionnaire (e.g., the Hospital Anxiety and Depression Scale-Anxiety subscale or a similar instrument). The outcome is the change from baseline to 16 weeks in anxiety total score, with higher scores indicating greater anxiety. Typical anxiety scales have ranges such as 0-21 (HADS-A) or 0-63 (BAI); enter the exact range that matches the scale you are using. |
Baseline and 16 weeks (end of treatment)
|
|
Change from baseline in health-related quality of life
Ramy czasowe: Baseline and 16 weeks (end of treatment)
|
Health-related quality of life will be assessed using a validated questionnaire (e.g., the MSQoL-54 or a comparable instrument). The outcome is the change from baseline to 16 weeks in the quality-of-life total score or composite score. For instruments scored 0-100, higher scores typically indicate better quality of life; specify the exact scoring range and direction according to your chosen measure. |
Baseline and 16 weeks (end of treatment)
|
Współpracownicy i badacze
Sponsor
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Objawy neurologiczne
- Choroby Układu Nerwowego
- Choroby Autoimmunologiczne
- Choroby układu odpornościowego
- Objawy behawioralne
- Manifestacje neurobehawioralne
- Demielinizacyjne choroby autoimmunologiczne, OUN
- Choroby Autoimmunologiczne Układu Nerwowego
- Choroby demielinizacyjne
- Zaburzenia percepcyjne
- Stany patologiczne, oznaki i objawy
- Zachowanie
- Objawy i symptomy
- Ból
- Stwardnienie rozsiane
- Depresja
- Zmęczenie
- Agnozja
- Lecznictwo
- Fizjoterapia
- Techniki ruchu ćwiczeń
Inne numery identyfikacyjne badania
- STUDY2025-0648-MOD001
- MB-2110-38597 (Inny numer grantu/finansowania: National Multiple Sclerosis Society)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .